ArticleActa pharmacologica Sinica2025

Ivacaftor, a CFTR potentiator, synergizes with osimertinib against acquired resistance to osimertinib in NSCLC by regulating CFTR-PTEN-AKT axis.

Yue-Kang Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.